Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of autologous bone marrow-derived mesenchymal progenitor cells (MSV) in xerostomia after radiotherapy
2018-001720-19Phase 2Active
- Sponsor
- Institut de Teràpia Regenerativa Tissular
- Start
- Nov 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MSV-CMT in xerostomia and radiation-induced hyposalivation (RIX), sponsored by Institut de Teràpia Regenerativa Tissular. Primary endpoints: Change in OHIP-14-sp questionnaire score and Change in visual analogue scale (VAS/EVA) for xerostomia. Started Nov 2018; status: active.
02
Drugs
MSV-CMT
03
Conditions
xerostomiaradiation-induced hyposalivation (RIX)
Beyond the preview
Go deeper on 2018-001720-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001720-19.